← Leaderboards
Jeffrey Smith
Luna Innovations, Inc.
$1,659,487
Attributed
$1,659,487
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $597.5K · FY2005–09$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$1,659,487 · 3
By mechanism
R44$1,095,351 · 1
R43$564,136 · 2
Top collaborators
No co-investigators on record.
Most similar at Luna Innovations, Inc.
Same institution · by research overlap
- Michael J Danilich$3,717,543
- Valeriy Bezmelnitsyn$224,997
Others in their field
Top investigators on “Universities”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$507,483,583
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Jeffrey P Krischer · University Of South Florida$463,124,587
- Mitchell J Malone · Texas A&M Research Foundation$353,400,900
Research focus
UniversitiesInhibitor/AntagonistSignal TransductionCellsKinase InhibitorClinical ApplicationInnovationProgramsVirginiaAnimal ModelEventSpecificityDesignBiodefenseBinding (Molecular Function)AerosolsBenchmarkingExcretory FunctionExhibitsChargeBacteriaAnalogAntimicrobialDrug Kinetics
Grant awards (4)
Development of RSK Inhibitors as Novel Therapeutics for Yersinia pestis$497,899
R44 · FY2009 · AI · contact PI
Development of RSK Inhibitors as Novel Therapeutics for Yersinia pestis$597,452
R44 · FY2008 · AI · contact PI
Development of Kinase-specific Molecular Markers For Cell-Based Assays$129,043
R43 · FY2007 · GM · contact PI
Validation of a RSK-inhibitor as a Novel Therapeutic for$435,093
R43 · FY2005 · AI